Kabir Nath: And Tom, to your second question, I would say we still have a lot of work to do to actually finalize the profile for TRD, let alone PTSD. So again, we couldn’t — genuinely couldn’t comment on how many administrations we would see for PTSD, what durability we might expect to see in a subsequent trial and so on. So, honestly, premature to comment on how these would relate to each other commercially.
Operator: And our next question comes from the line of Sumant Kulkarni from Canaccord Genuity.
Sumant Kulkarni: Nice to see the PTSD data. I have two. So first, on COMP360, how can the company optimally mitigate the risk associated with suicidal ideation in trials, given both TRD and PTSD have high background rate of this type of event in patients to start with? And second, it’s very nice to see Dr. Michael Gold on board. Given Michael’s extensive experience with multi-asset companies, how do you think the strategy of COMPASS might evolve going forward in terms of the types of compounds that COMPASS might be looking at?
Guy Goodwin: I think the standard answer to this is really that we don’t recruit patients who are actively suicidal, because it really doesn’t seem ethical to randomize them to no treatment or low treatment. And I think everyone takes that approach. Ultimately, it’s impossible to completely exclude the existence of suicidality in these sorts of patient populations. Otherwise, you’re not studying a truly generalizable sample. But we insist that our preparation and the support during the administration optimizes the preparedness of patients. And we think for that reason, we’re seeing these relatively minor changes in the rating scale. Bear in mind that we have had no attempted suicides or suicides in any of our studies. And what we’re seeing and describing here are changes on a scale, which is sub-threshold for actual events that you would classify as clinically serious, particularly in this study.
Kabir Nath: And Sumant to your question, yes, I think, first, we’ve always said that we need actual credibility with COMP360. And I believe with our progress with TRD and what we’ve announced today with PTSD, we’re well underway to doing that. We do have discovery assets, some of which we could be in a position to advance into first in humans in the relatively short time frame. But I think having established ourselves as a credible developer, late stage developer of drugs, it absolutely is part of our thoughtful strategy to how we might expand into other assets over time. But recognizing, again, that’s not a given. We have to demonstrate credibility and success with our lead assets, and I think we’re well on the way to doing that.
Operator: [Operator instructions] And our next question comes from the line of Elemer Piros from Rodman.
Elemer Piros: Maybe a question to Guy. Guy, I’m looking at the PTSD results with MDMA from the Phase III trial. And it appears that it takes about 12 weeks to reach maximum benefit with MDMA plus therapy. How does that compare to what you observed with a single dose of COMP360?
Guy Goodwin: Our CAPS-5 number is taken at four weeks. It’s the first measure we take because it’s a four week measure. And of course, that shows the full effect at four weeks. And it’s sustained out at 12 weeks using the same measure. So that’s what we appear to see. We will have an even finer-grained evidence for early, very speedy onset from other measures that we took from patients that we don’t yet have available to show you, but we will have them in due course.
Elemer Piros: So do you believe that the results with MDMA are probably due to the second dose, the third dose amplifying the effect and with the end results being about the same reduction in CAPS-5 as what you see?
Guy Goodwin: Yes, that’s what we all see, yes.
Operator: Thank you. This does conclude the question-and-answer session of today’s program. I’d like to hand the program back to management for any further remarks.
Kabir Nath: So just to say thanks all for your participation. As I say, I think as we’ve heard also during the questions, we’re very encouraged by this robust signal we’ve seen in PTSD. We are working to look at what a future plan for the program might be. We continue to execute on the timelines we established in February for COMP 005 and COMP 006 and TRD, and I think, therefore, we are looking forward to exciting news later in the year. So thanks everyone for your participation. Thanks for your support. I wish everyone a very good rest of the day.
Operator: Thank you, ladies and gentlemen, for your participation in today’s conference. This does conclude the program. You may now disconnect. Good day.
